Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A7 | Q9GZV3 | 6/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.35 |
| ▸ | WDR5 | P61964 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 2/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29620712 | 1.00 | SLC5A7 (0.37) | SLC5A7RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL24345313 | 0.93 | SLC5A7 (0.36) | SLC5A7RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL24345469 | 0.93 | SLC5A7 (0.36) | SLC5A7RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL24345312 | 0.93 | SLC5A7 (0.36) | SLC5A7RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL24345470 | 0.93 | SLC5A7 (0.36) | SLC5A7RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL24345709 | 0.92 | GRM7 (0.36) | SLC5A7RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL29620729 | 0.92 | GRM7 (0.36) | SLC5A7RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL24345280 | 0.92 | GRM7 (0.36) | SLC5A7RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL24345274 | 0.89 | MEN1 (0.37) | SLC5A7RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL26527179 | 0.87 | MAPT (0.35) | SLC5A7RAB9AMEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119398-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119398-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | VIP, ACE, FURIN | SLC5A7 2873/4885RAB9A 655/4885MEN1 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.